NYSE:ATNM
Actinium Pharmaceuticals, Inc.
Actinium Pharmaceuticals develops targeted alpha therapies for oncology using its proprietary Actinium-225 platform to treat hard-to-treat cancers.
Key Metrics
Investment Thesis
Bull Case
Investors may consider Actinium for its proprietary Actinium-225 platform which addresses a critical shortage in targeted alpha therapy supply. The company's substantial deferred revenue suggests potential future commercialization or partnership milestones that could unlock value once clinical trials succeed. Successful registration of an oncology product could transform the company from a cash-burning biotech into a profitable revenue generator.
Bear Case
The stock carries extreme downside risk due to deepening losses and a massive deficit in retained earnings indicating unsustainable burn without new capital. With zero or near-zero revenue for three consecutive years, the business model relies entirely on external financing which may dry up in a high-interest rate environment. The lack of commercial traction makes valuation speculative, as any failure in clinical trials could lead to total value erosion.
About Actinium Pharmaceuticals, Inc.
Actinium Pharmaceuticals Inc. is a biopharmaceutical company focused on developing novel therapeutics, primarily targeting oncology indications through its proprietary Actinium-225 platform. The company serves the specialized healthcare market with pipeline assets aimed at treating difficult-to-treat cancers. Key products and technologies center around targeted alpha therapy (TAT) utilizing their unique isotope production capabilities.
Analysis
Management Discussion
Actinium reported a net loss of -$38.2M for the latest period, continuing a trend of increasing losses from -$33.0M in 2022 to -$48.8M in 2023 before a slight recovery. The company burned through cash at a rate exceeding its interest income of $3.9M, resulting in a net change in cash of -$3.8M. Despite the loss, the company maintained a healthy current ratio with current assets of $74.5M against current liabilities of $8.1M, supported by significant paid-in capital of $408.6M.
Industry Overview
The biopharmaceutical industry is currently undergoing a shift towards novel modalities like radiopharmaceuticals and immuno-oncology combinations to overcome resistance in standard cancer treatments. Actinium operates in the high-risk, high-reward segment of oncology where first-mover advantages in novel isotopes can capture significant market share. Regulatory pathways for alpha-emitting therapies remain less established than traditional drug classes, adding complexity to the competitive landscape.
Financial Statements
Income Statement
Balance Sheet
Cash Flow
| Metric | 2022 | 2023 | 2024 |
|---|---|---|---|
| Revenue | $1.0M | $81.0K | $0 |
| Cost of Revenue | $0 | $0 | $0 |
| Gross Profit | $1.0M | $81.0K | $0 |
| Operating Expenses | $35.1M | $52.0M | $42.1M |
| Operating Income | $-34.1M | $-51.9M | $-42.1M |
| R&D | $23.1M | $38.7M | $30.0M |
| G&A | $12.0M | $13.3M | $12.1M |
| Stock-Based Comp | $2.8M | $3.8M | $5.3M |
| D&A | $699.0K | $790.0K | $197.0K |
| Depreciation | $152.0K | $207.0K | $197.0K |
| Other OpEx | $0 | $0 | $0 |
| Non-Operating Income | $0 | $0 | $0 |
| Interest Income | — | — | $3.9M |
| Pre-Tax Income | $-34.1M | $-51.9M | $-42.1M |
| Income Tax | $-1.1M | $-3.1M | $-3.9M |
| Continuing Ops | $-33.0M | $-48.8M | $-38.2M |
| Discontinued Ops | $0 | $0 | $0 |
| Net Income | $-33.0M | $-48.8M | $-38.2M |
| Minority Interest | $0 | $0 | $0 |
| Net to Common | $-33.0M | $-48.8M | $-38.2M |
| Metric | 2022 | 2023 | 2024 |
|---|---|---|---|
| Current Assets | $110.9M | $78.3M | $74.5M |
| Cash & Equivalents | $108.9M | $76.7M | $72.9M |
| Prepaid Expenses | $1.6M | $1.6M | $1.6M |
| Other Current Assets | $396.0K | $0 | $0 |
| Long-Term Assets | $3.2M | $3.2M | $2.4M |
| PP&E (Net) | $604.0K | $550.0K | $364.0K |
| Operating Leases | $2.3M | $2.3M | $1.7M |
| Other LT Assets | $305.0K | $343.0K | $344.0K |
| Total Assets | $114.2M | $81.4M | $76.9M |
| Current Liabilities | $10.6M | $8.5M | $8.1M |
| Current Leases | $494.0K | $530.0K | $569.0K |
| Other Current Liab | $10.1M | $8.0M | $7.6M |
| Long-Term Liabilities | $37.1M | $36.6M | $36.0M |
| LT Operating Leases | — | $1.6M | $984.0K |
| Other LT Liab | — | $35.0M | $9.0K |
| Total Liabilities | $47.7M | $45.1M | $44.1M |
| Shareholders' Equity | $66.5M | $36.4M | $32.8M |
| Paid-In Capital | $355.2M | $373.9M | $408.6M |
| Retained Earnings | $-288.8M | $-337.6M | $-375.8M |
| Total L&E | $114.2M | $81.4M | $76.9M |
| Metric | 2022 | 2023 | 2024 |
|---|---|---|---|
| Net Income (CFO) | $-33.0M | $-48.8M | $-38.2M |
| Non-Cash Adjustments | $2.9M | $4.2M | $6.1M |
| Working Capital Changes | $38.8M | $-2.7M | $-902.0K |
| Cash from Operations | $8.6M | $-47.3M | $-33.1M |
| Capital Expenditures | $366.0K | $153.0K | $11.0K |
| Cash from Investing | $-366.0K | $-153.0K | $-11.0K |
| Cash from Financing | $23.1M | $14.9M | $29.3M |
| FX Effect | $0 | $0 | $0 |
| Net Change in Cash | $31.4M | $-32.6M | $-3.8M |
| Beginning Cash | $78.2M | $109.6M | $77.0M |
| Ending Cash | $109.6M | $77.0M | $73.2M |
Frequently Asked Questions
How does Actinium Pharmaceuticals, Inc. make money?
The company's financials reflect a pre-revenue biotech model with minimal current revenue ($0.1M in 2023) driven entirely by research and development activities. R&D expenses of $30.0M focus on oncology pipeline progression, while general and administrative costs of $12.1M support corporate operations. A significant portion of assets is held in long-term deferred revenue ($35.0M), suggesting potential future obligations or milestone payments from external partners not yet realized as cash flow.
What are the main risks for ATNM?
The company faces severe liquidity risk with a negative operating cash flow of -$33.1M and a substantial retained earnings deficit of -$375.8M, requiring continuous capital raises. Revenue is negligible compared to high burn rates, creating dependency on equity issuance or partnership milestones for survival. Regulatory approval risks are high given the novel nature of alpha-emitting radiopharmaceuticals and the complexity of clinical development in oncology.
What is ATNM's competitive advantage?
Actinium holds a strategic moat through its proprietary Actinium-225 supply chain, which is critical for targeted alpha therapy and difficult to replicate due to production constraints. The company's focus on novel modalities like TAT differentiates it from competitors relying on traditional small molecules or antibodies. Its partnership history often provides access to external funding streams, evidenced by the $29.3M in cash flow from financing.
Related Companies
Not financial advice. All content is for informational purposes only. Data may contain errors. Consult a qualified financial advisor before making investment decisions.